Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Jain, Milpitas

Ajay Jain, Milpitas, CA US

Patent application numberDescriptionPublished
20100264391EPI SUBSTRATE WITH LOW DOPED EPI LAYER AND HIGH DOPED SI SUBSTRATE LAYER FOR MEDIA GROWTH ON EPI AND LOW CONTACT RESISTANCE TO BACK-SIDE SUBSTRATE - The fabrication of seek-scan probe (SSP) memory devices involves processing on both-sides of a wafer. However, there are temperature restrictions on the mover circuitry side of the wafer and doping level constrains for either side of wafer. Using a low doped EPI layer on a highly doped substrate solves this issue and provides good STO growth.10-21-2010
20100276788METHOD AND DEVICE OF PREVENTING DELAMINATION OF SEMICONDUCTOR LAYERS - Embodiments of the present invention describe a method and device of preventing delamination of semiconductor layers in a semiconductor device. The semiconductor device comprises a substrate with an interlayer dielectric (ILD). A protection layer is deposited on the ILD. Next, a getter layer is formed on the protection layer to remove any native oxides on the protection layer. A capping layer is then deposited on the getter layer to prevent oxidation of the getter layer. Next, a semiconductor layer is formed on the capping layer. An oxide layer is then deposited on the semiconductor layer. Subsequently, a buffered oxide etch solution is used to remove the oxide layer. By removing the native oxides on the protection layer, the getter layer prevents the reaction between the buffered oxide etch solution and the native oxides which may cause delamination of the semiconductor layer and protection layer.11-04-2010

Akash Jain, Milpitas, CA US

Patent application numberDescriptionPublished
20110093830Integrated Circuit Optimization Modeling Technology - A design optimization method for a target circuit design specified by a machine-readable file, comprises providing a computer-implemented model as a function of a set of characteristics of circuit designs of circuit optimization achievable due to a circuit modification procedure, such as timing constrained gate length modification for leakage power reduction. Using values of said set of characteristics for the target circuit design, the computer-implemented model is applied to the target circuit design to produce an indication of susceptibility of the target circuit design to optimization. The model can be produced using Monte Carlo simulations of a set of virtual designs, and fitting a function of said characteristics to the results.04-21-2011

Amit K. Jain, Milpitas, CA US

Patent application numberDescriptionPublished
20100291186Transdermal Administration of Tamsulosin - In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier.11-18-2010

Rachna Jain, Milpitas, CA US

Patent application numberDescriptionPublished
20090104243Drug cores for sustained release of therapeutic agents - A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.04-23-2009
20090220615Main Chain Acid-Degradable Polymers for the Delivery of Bioactive Materials - Novel main chain acid degradable polymer backbones and drug delivery systems comprised of materials capable of delivering bioactive materials to cells for use as vaccines or other therapeutic agents are described. The polymers are synthesized using monomers that contain acid-degradable linkages cleavable under mild acidic conditions. The main chain of the resulting polymers readily degrade into many small molecules at low pH, but remain relatively stable and intact at physiological pH. The new materials have the common characteristic of being able to degrade by acid hydrolysis under conditions commonly found within the endosomal or lysosomal compartments of cells thereby releasing their payload within the cell. The materials can also be used for the delivery of therapeutics to the acidic regions of tumors and other sites of inflammation.09-03-2009
20090264861Lacrimal implants and related methods - Lacrimal implants and related methods providing secure retention within the lacrimal punctum of an eye are described. The lacrimal implants can comprise a implant body configured for at least partial insertion through the lacrimal punctum and into a lacrimal canaliculus. The implant body can include a deformable retention structure that can be configured to substantially encapsulate an expandable retention element. In some examples, the expandable retention element can include a fluid absorbing material, which can be exposed to fluid such as via a fluid permeable retainer or a fluid permeable aperture. As the fluid absorbing material retains fluid (i.e., upon acceptance of fluid into the retention structure), its size increases and its shape can change to urge one or more portions of the retention structure outward, such as against a wall of the lacrimal canaliculus, thereby securely retaining the lacrimal implant within the punctum.10-22-2009
20100034870COMPOSITE LACRIMAL INSERT AND RELATED METHODS - Lacrimal implants, methods of making lacrimal implants, and methods of treating ocular, respiration or other diseases or disorders using lacrimal implants are disclosed.02-11-2010
20100274224LACRIMAL IMPLANT BODY INCLUDING COMFORTING AGENT - Lacrimal implants for treating ocular diseases are disclosed. More particularly, lacrimal punctal plugs, methods of making such plugs, and methods of treating ocular diseases using such plugs are disclosed.10-28-2010